The largest randomized trial of its kind to date found noninferior survival and better arm morbidity among patients with breast cancer who did not undergo completion axillary lymph node dissection.

Applies to most patients with one or two positive sentinel lymph nodes ...

Omitting completion axillary lymph node dissection does not increase risk for death for patients with clinically node-negative breast cancer, but it does significantly improve arm distress.Data from ...

Five-year OS was 94.4% with ALND omission vs 93.4% with completion ALND (HR 0.89), confirming non-inferiority; breast cancer–specific survival was similarly high in both arms. Inclusion of mastectomy ...

Researchers at the UAB and the Hospital del Mar Research Institute have confirmed that patients with the presence of NK lymphocytes around tumors have a better response to treatment. This confirms the ...

A CANCER jab available on the NHS can melt away tumours when patients have run out of options, a trial found. Triple-action ...

Lymphocyte-depleted Hodgkin’s lymphoma (LDHL) is a rare subtype of Hodgkin’s lymphoma, a cancer that develops in the lymphatic system. Hodgkin’s lymphoma (HL) is an uncommon cancer of the lymphatic ...